Follicular hyperkeratosis as a manifestation of Sézary syndrome

F. Al‐Niaimi,N. Cox,W. Taylor

DOI: https://doi.org/10.1111/j.1365-2133.2009.09599.x

IF: 11.113

2010-03-01

British Journal of Dermatology

Abstract:MADAM, Follicular hyperkeratosis or ‘spinulosis’ has been reported as a paraneoplastic feature of multiple myeloma, originally described in 1944 by Heidenstrom and Tottie in a 39-year-old patient with multiple myeloma who presented with follicular keratoses on the face. Expanding the spectrum of follicular keratoses as a marker of systemic disease, we describe prominent, morphologically similar lesions affecting the face and scalp in two patients with Sézary syndrome, present at the outset in both cases. Patient 1 was a 60-year-old man who gave a 1-month history of intensely pruritic macular erythema, which had started on the head but rapidly spread to involve the whole body. One year previously he had had a transient rash on the legs with mixed features of eczema and psoriasis, including onycholysis, which had resolved following topical treatment. At presentation he described shivering and general malaise. Examination revealed generalized erythroderma, florid follicular filiform keratoses, which were most prominent on the head and scalp (Fig. 1a), marked diffuse palmoplantar and subungual hyperkeratosis. There was hepatomegaly (related to alcohol consumption) but no splenomegaly or lymphadenopathy. A presumptive diagnosis of pityriasis rubra pilaris was made. Skin biopsies on two occasions both demonstrated a dense pleomorphic T-cell infiltrate in keeping with cutaneous T-cell lymphoma surrounding a keratotic spicule (Fig. 1b). Total white cell count was elevated at 17Æ0 · 10 L with 13% (normal 0–5%) circulating Sézary cells. Bone marrow examination showed fewer atypical lymphocytes; those present were felt to be due to admixture with circulating cells. Treatment with topical corticosteroids produced some improvement in the skin but the blood film appearances remained unchanged, and psoralen plus ultraviolet A (PUVA) therapy was not tolerated. Chlorambucil treatment was commenced, given for 6 weeks followed by a 2-week break. The initial dose was 6 mg daily, increased to 10 mg daily for the second and third courses but subsequently reduced to 4 mg daily for the final three courses because of moderate thrombocytopenia. This produced good improvement within the first 2 months; after three courses, the erythroderma and keratoses had fully resolved with no relapse 2 years after completing six courses of chlorambucil. Patient 2 was a 57-year-old man who developed increasingly intense erythematous macular eruption over 4 months. At the time of presentation he was erythrodermic and had florid filiform keratoses of the palms, soles, scalp, ears and nose (Fig. 2). Skin biopsy demonstrated an atypical T-cell infiltrate in keeping with mycosis fungoides (MF). Full blood